When making a myeloproliferative neoplasm (MPN) treatment decision, several factors come into play. Dr. Brady Stein explains what criteria he considers to determine the optimal approach for a patient’s unique situation and specific MPN. Dr. Brady Stein is a hematologist focusing on myeloproliferative neoplasms (MPNs) at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Learn more about Dr. Stein, here: [ Ссылка ].
Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome.
Subscribe now to receive the latest news on cancer treatment and research: powerfulpatients.org/connect
What Factors Guide Treatment Choices for ET, PV & MF?
Теги
MPNMyeloproliferative NeoplasmPolycythemia VeraMyelofibrosisEssential ThrombocythemiaPVETphlebotomybloodlettingdriver mutationsomatic mutationbone marrow biopsyfibrosisMPL mutationCalreticulin mutationJAK mutationJAK2V617F mutationthrombotic eventthrombosisblood clotsplenomegalymomelotinibpacritinibInterferonJAK inhibitorRopeginterferoncytoreductive therapystem cell transplantanemiacombination therapycomorbiditiesDr. Brady Stein